Abstract:Recombinant antibodies such as nanobodies are progressively demonstrating to be a valid alternative to conventional monoclonal antibodies also for clinical applications. Furthermore, they do not solely represent a substitute for monoclonal antibodies but their unique features allow expanding the applications of biotherapeutics and changes the pattern of disease treatment. Nanobodies possess the double advantage of being small and simple to engineer. This combination has promoted extremely diversified approaches to design nanobody-based constructs suitable for particular applications. Both the format geometry possibilities and the functionalization strategies have been widely explored to provide macromolecules with better efficacy with respect to single nanobodies or their combination. Nanobody multimers and nanobody-derived reagents were developed to image and contrast several cancer diseases and have shown their effectiveness in animal models. Their capacity to block more independent signaling pathways simultaneously is considered a critical advantage to avoid tumor resistance, whereas the mass of these multimeric compounds still remains significantly smaller than that of an IgG, enabling deeper penetration in solid tumors. When applied to CAR-T cell therapy, nanobodies can effectively improve the specificity by targeting multiple epitopes and consequently reduce the side effects. This represents a great potential in treating malignant lymphomas, acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma and solid tumors. Apart from cancer treatment, multispecific drugs and imaging reagents built with nanobody blocks have demonstrated their value also for detecting and tackling neurodegenerative, autoimmune, metabolic, and infectious diseases and as antidotes for toxins. In particular, multi-paratopic nanobody-based constructs have been developed recently as drugs for passive immunization against SARS-CoV-2 with the goal of impairing variant survival due to resistance to antibodies targeting single epitopes. Given the enormous research activity in the field, it can be expected that more and more multimeric nanobody molecules will undergo late clinical trials in the next future. Systematic Review Registration.

Current Status of Nanobody Technology: Applications in Disease Diagnosis and Therapy

Small Antibodies with Big Applications: Nanobody-Based Cancer Diagnostics and Therapeutics

[Application of nanobody in cancer treatment].

Recent advances of nanobody applications in diagnosis and detection

Research Progress of Nanobodies in Diagnosis and Therapy of Tumor

Nanobody: a promising toolkit for molecular imaging and disease therapy

Nanobodies: From High-Throughput Identification to Therapeutic Development

Application Progress of the Single Domain Antibody in Medicine

Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer

Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy

Targeted Nanobody-Based Molecular Tracers for Nuclear Imaging and Image-Guided Surgery

Nanobody Technology: A Versatile Toolkit for Microscopic Imaging, Protein–Protein Interaction Analysis, and Protein Function Exploration

[Recent advances in the application of nanobody technology: a review].

Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy

Nanobodies: from Structure to Applications in Non-Injectable and Bispecific Biotherapeutic Development.

Nanobodies: a promising approach to treatment of viral diseases

NANOBODY® Molecule, a Giga Medical Tool in Nanodimensions

Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment

Heterologous Expression of Nanobodies: a Recent Progress

Nanobodies: From Serendipitous Discovery of Heavy Chain-Only Antibodies in Camelids to a Wide Range of Useful Applications.

Single domain antibody: Development and application in biotechnology and biopharma